EU antitrust regulators brought charges against Teva over an illegal deal with its Cephalon unit to delay selling the generic version of the Cephalon’s blockbuster sleep disorder drug.
According to the commission, the agreement was made in 2009, following a lawsuit over an alleged infringement by Teva of Cephalon’s processing patents on Provigil (modafinil). Teva then acquired Cephalon in 2011.
Teva is denying any anti-competitive behavior.
U.S. antitrust authorities previously fined the company $1.2 billion in 2015 over the same issue.
Read the Reuters coverage